STOCK TITAN

Tempus AI (TEM) Stock News, Oct-Nov 2025

TEM NASDAQ

Tempus AI, Inc. (NASDAQ: TEM) is a healthcare technology company that applies artificial intelligence and multimodal data to precision medicine, with a strong focus on oncology and health information services. The Tempus news stream highlights how the company’s platform, genomic testing capabilities, and data-driven tools are used in collaborations, research, and commercial partnerships.

Readers can follow announcements about Tempus’s strategic collaborations with leading health systems and academic medical centers, such as multi-year precision oncology initiatives and efforts to expand access to genomic testing for cancer patients. News items also cover research partnerships with nonprofit foundations, including multi-omic studies designed to build comprehensive datasets for specific diseases like follicular lymphoma.

Tempus frequently reports on its participation in major scientific conferences, where it presents abstracts based on its de-identified multimodal database and tools like Tempus Lens. These updates include studies on tumor genomics, immune microenvironments, biomarkers, and real-world outcomes across a range of cancers, including gastrointestinal, breast, and other solid tumors. In addition, the news feed features corporate and financial updates, such as preliminary revenue results, contract value milestones, and appearances at investor conferences.

By reviewing the latest TEM news, investors and healthcare professionals can see how Tempus’s AI-enabled precision medicine solutions are being applied in clinical settings, research collaborations, and life sciences partnerships. This page is a resource for tracking ongoing developments in Tempus’s diagnostics, data and applications businesses, as well as its role in advancing data-driven approaches to cancer care and therapeutic development.

Rhea-AI Summary

Tempus (NASDAQ: TEM) launched a multi-year research study in collaboration with the Institute for Follicular Lymphoma Innovation (IFLI) to build a comprehensive, multi-omic dataset for follicular lymphoma (FL).

The study will enroll FL patients and apply next-generation sequencing, proteomics, and methylation analysis to integrate molecular profiling with real-world clinical data. The collaboration is Tempus’ first study partnership with a nonprofit foundation and aims to support biomarker discovery, whole-genome sequencing validation, and precision-medicine research.

FL represents roughly 10–20% of U.S. non-Hodgkin lymphoma cases; the release notes ~20% of patients progress within two years after chemoimmunotherapy and a 50% five-year overall survival, underscoring research needs.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.79%
Tags
none
-
Rhea-AI Summary

Tempus (NASDAQ: TEM) announced six abstracts accepted for presentation at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2025, held November 5–9 in National Harbor, Maryland.

Key research includes: a multi-omic Immune Profile Score (IPS) predicting ICI outcomes in rare advanced solid cancers (n=90) and MSS colorectal cancer (n=46); a MAIT cell prevalence analysis across 190,189 patients; an automated TargetR multi-omics framework; an ultrahigh TMB ≥40 mut/MB analysis in 17,449 patients showing improved real-world response and survival; and AR alteration effects in 1,556 castration-resistant prostate cancer patients.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.64%
Tags
none
-
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.64%
Tags
Rhea-AI Summary

Tempus (NASDAQ:TEM) will participate in the Stifel 2025 Healthcare Conference in New York City on Thursday, November 13, 2025. Jim Rogers, Tempus chief financial officer, will appear in a fireside chat at 10:00 AM ET. A live webcast will be available via the company’s investor relations events page or the provided webcast link for remote viewers.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.45%
Tags
conferences
-
Rhea-AI Summary

Tempus (NASDAQ:TEM) will report third-quarter 2025 financial results on November 4, 2025.

The company will hold its earnings conference call at 4:30 PM ET featuring Founder and CEO Eric Lefkofsky and CFO Jim Rogers. A live audio webcast will be available on Tempus’ Investor Relations events page. Call access details: Conference ID 5436492; USA & Canada toll-free (800) 715-9871; U.S. toll (646) 307-1963. Live webcast link provided for listeners.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.62%
Tags
conferences earnings
-
Rhea-AI Summary

Ambry Genetics (NASDAQ: TEM) announced publication on October 20, 2025 of a 10-year peer-reviewed study in Genetics in Medicine analyzing exome reanalysis across racial, ethnic, and ancestral groups.

The study found lower rates of provider-initiated exome reanalysis for Hispanic and Latino (22%), Asian (21%), and African American and Black (17%) patients versus White patients (25%). Reanalysis increased positive results across all groups. Ambry's Patient for Life™ program provides ongoing laboratory-driven reanalysis without a provider request, removing the provider-referral barrier and aiming to improve equity in access to updated genetic findings.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.32%
Tags
none
Rhea-AI Summary

Tempus (NASDAQ: TEM) announced a multi-year collaboration with Whitehawk Therapeutics (NASDAQ: WHWK) to use Tempus’ de-identified multimodal real-world dataset and AI platform to advance biomarker-driven oncology research.

The agreement will support Whitehawk’s clinical trial design and indication prioritization for its antibody drug conjugate (ADC) portfolio targeting PTK7, MUC16, and SEZ6, with a focus on cancers such as lung and gynecological indications. The partnership will evaluate concordance between RNA and IHC expression to explore RNA testing as an objective, reproducible, scalable alternative for patient identification.

Date announced: October 16, 2025.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.97%
Tags
partnership
-
Rhea-AI Summary

Tempus (NASDAQ:TEM) announced six abstracts accepted for presentation at ESMO Congress 2025 (Oct 17–21, 2025) in Berlin: two oral presentations and four posters.

Key highlights include an OPTIC RCC phase II RNAseq‑guided cohort (26 angiogenic patients; 21 with post‑baseline scans: 100% tumor burden reduction; RECIST: 71% partial response, 29% stable disease) and a 425‑patient analysis linking LAG3 RNA expression to immunotherapy objective response rates in mRCC. Other posters report real‑world immunogenomic and biomarker findings across prostate, NSCLC, biliary tract, and integrin beta‑6 research using Tempus de‑identified data and Lens analytics.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.27%
Tags
none
-
Rhea-AI Summary

Tempus (NASDAQ: TEM) was selected by the Advanced Research Projects Agency for Health (ARPA-H) on October 9, 2025 to provide CRO and testing services for the ADAPT program, which targets adaptive precision therapies for metastatic non-small cell lung, breast, and colorectal cancers.

Tempus will supply its AI-enabled diagnostics (xE, xR, xF+, xM), use its Compass CRO to manage trial operations across sites, and perform data integration and harmonization for the study to support early detection of tumor resistance and dynamic treatment adjustments.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.85%
Tags
none
Rhea-AI Summary

Ambry Genetics, a subsidiary of Tempus AI (NASDAQ: TEM), has announced significant improvements to its Ambry CARE Program®, enhancing breast cancer risk assessment capabilities. The update integrates breast density measurements into the Tyrer-Cuzick (TC) scoring system within electronic health records (EHR), enabling more accurate risk assessments.

The enhanced platform addresses a critical healthcare gap, as 93% of high-risk women who qualify for breast MRI screening currently don't receive it. The system now includes four TC score options aligned with BI-RADS breast density categories (A-D), helping clinicians identify patients with a 20% or higher risk who may need increased screening. A recent study in the Journal of the National Comprehensive Cancer Network validated CARE's accuracy, demonstrating 99.5% accuracy in interpreting NCCN Guidelines®.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.02%
Tags
none

FAQ

What is the current stock price of Tempus AI (TEM)?

Tempus AI (TEM) last closed at $54.04.

What is the market cap of Tempus AI (TEM)?

The market cap of Tempus AI (TEM) is approximately $9.9B.